Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia by Bilz, Stefan et al.
 Copyright © 2004 by the American Society for Biochemistry and Molecular Biology, Inc.
 
174 Journal of Lipid Research
 
Volume 45, 2004
 
This article is available online at http://www.jlr.org
 
Effects of atorvastatin versus fenofibrate on apoB-100 
and apoA-I kinetics in mixed hyperlipidemia
 
Stefan Bilz,* Stephan Wagner,
 
†
 
 Michaela Schmitz,
 
†
 
 Andrea Bedynek,
 
†
 
 Ulrich Keller,
 
1,
 
* 
and Thomas Demant
 
†,§
 
Division of Endocrinology, Diabetology, and Clinical Nutrition,* University Hospital Basel, Basel, Switzerland; 
Institute of Clinical Chemistry,
 
†
 
 Klinikum der Ludwig-Maximilians-University, Grosshadern, Munich, 
Germany; and Institute of Clinical Chemistry,
 
§
 
 Krankenhaus Dresden-Friederichstadt, Dresden, Germany
 
Abstract Kinetics of apo B and apo AI were assessed in
8 patients with mixed hyperlipidemia at baseline and after 8
weeks of atorvastatin 80 mg q.d. and micronised fenofi-
brate 200 mg q.d. in a cross-over study. Both increased he-
patic production and decreased catabolism of VLDL accounted
for elevated cholesterol and triglyceride concentrations at
baseline. Atorvastatin significantly decreased triglyceride,
total, VLDL and LDL cholesterol and apo B concentrations
(
 

 
65%, 
 

 
36%, 
 

 
57%, 
 

 
40% and 
 

 
33%, respectively, 
 
P
 
 
 

 
0.05). Kinetic analysis revealed that atorvastatin stimulated
the catabolism of apo B containing lipoproteins, enhanced
the delipidation of VLDL
 
1
 
 and decreased VLDL
 
1
 
 produc-
tion. Fenofibrate lowered triglycerides and VLDL choles-
terol (
 

 
57% and 
 

 
64%, respectively, 
 
P
 
 
 

 
 0.05) due to en-
 
hanced delipidation of VLDL
 
1
 
 and VLDL
 
2
 
 and increased
VLDL
 
1
 
 catabolism. Changes of HDL particle composition ac-
counted for the increase of HDL cholesterol during atorva-
 
statin and fenofibrate (18% and 23%, 
 
P
 
 
 

 
 0.01). Only fenofi-
brate increased apo AI concentrations through enhanced apo
AI synthesis (45%, 
 
P
 
 
 

 
 0.05).  We conclude that atorvasta-
tin exerts additional beneficial effects on the metabolism of
apo B containing lipoproteins unrelated to an increase in
LDL receptor activity. Fenofibrate but not atorvastatin in-
creases apo AI production and plasma turnover.
 
—Bilz, S., S.
Wagner, M. Schmitz, A. Bedynek, U. Keller, and T. Demant.
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Mixed hyperlipidemia, i.e., the increase of both plasma
total cholesterol and triglycerides, refers to an etiologi-
cally heterogeneous lipoprotein phenotype that occurs in
both primary and secondary dyslipidemias. The usually as-
sociated decrease of HDL cholesterol and the shift in the
LDL size profile toward small, dense particles further con-
 
tribute to the considerable cardiovascular risk in affected
patients (1).
Among the currently available lipid-lowering com-
pounds, HMG-CoA reductase inhibitors, also referred to
as statins, and fibrates have been proven to effectively de-
crease cardiovascular morbidity and mortality in several
large-scale primary and secondary prevention trials dur-
ing the past two decades (2–8). Thus, current guidelines
recommend the use of these drugs both in patients with
established cardiovascular disease and in subjects at risk as
a result of preexisting hyperlipidemia (9). In patients with
mixed hyperlipidemia and moderately to severely in-
creased plasma triglycerides, therapy with either com-
pound may result in favorable changes of the lipoprotein
pattern. Classic studies demonstrated that the dose-depen-
dent decreases in plasma total and LDL cholesterol levels
during competitive inhibition of HMG-CoA reductase by
statin therapy are secondary to enhanced LDL receptor-
mediated lipoprotein catabolism (10). More recently, the
triglyceride-lowering capacity of statins has gained addi-
tional attention, and atorvastatin has been found to be
particularly efficacious, most likely secondary to its longer
duration of action and its enhanced lipid-lowering po-
tency (11, 12). Enhanced catabolism of apolipoprotein B
(apoB)-containing triglyceride-rich lipoproteins via the
LDL receptor pathway may in part explain the decrease in
plasma triglycerides elicited by statins. However, data ob-
tained from patients with LDL receptor-negative homozy-
gous familial hypercholesterolemia and animal models
clearly suggest that statins may also interfere with hepatic
lipoprotein production (13, 14). The effects of fibrates,
among them fenofibrate, on plasma lipids have been
found to result from the activation of the peroxisome pro-
liferator-activated receptor 
 

 
 (PPAR
 

 
) (15). Specifically,
 
Abbreviations: apoA-I, apolipoprotein A-I; apoB, apolipoprotein B;
d
 
3
 
-leucine, deuterated leucine; FCR, fractional catabolic rate; LPL, li-
poprotein lipase; PPAR
 

 
, peroxisome proliferator-activated receptor 
 

 
.
 
1 
 
To whom correspondence should be addressed.
e-mail: ukeller@uhbs.ch
 
Manuscript received 11 July 2003 and in revised form 17 September 2003.
Published, JLR Papers in Press, October 1, 2003.
DOI 10.1194/jlr.M300309-JLR200
 by guest, on Novem
ber 21, 2017
w
w
w
.jlr.org
D
ow
nloaded from
 
 Bilz et al.
 
Statin and fibrate effects on apolipoprotein metabolism 175
 
fibrates have been demonstrated to reduce hepatic triglyc-
eride production, to enhance delipidation and clearance
of triglyceride-rich lipoproteins, and to activate reverse
cholesterol transport (16). These alterations in lipid me-
tabolism are associated with a profound decrease of
plasma triglycerides, increased HDL cholesterol levels,
and a favorable shift in the density distribution of LDL to-
ward buoyant, less-atherogenic particles, whereas the ef-
fects on LDL cholesterol levels may vary. However, to our
knowledge, data regarding the comparative effects of
statins and fibrates on lipoprotein metabolism in the sub-
set of patients with mixed hyperlipidemia and moderately
to severely increased plasma triglyceride levels are not
available from the literature. Therefore, we performed
apoB and apolipoprotein A-I (apoA-I) kinetic studies us-
ing endogenous labeling of apoB and apoA-I with deuter-
ated leucine (d
 
3
 
-leucine) and multicompartmental mod-
eling to derive lipoprotein production and catabolic rates
in the basal state and after 8 weeks of therapy with either
atorvastatin or fenofibrate.
METHODS
 
Subjects
 
Eight male patients (age 51 
 

 
 4 years, mean body weight 86 
 

 
4 kg) with increased fasting triglyceride (3.7–26 mmol/l) and
normal to increased LDL cholesterol (2.4–5.9 mmol/l) levels
were selected from the lipid outpatient clinic at Basel University
Hospital. Eight male subjects with normal fasting plasma triglyc-
eride levels matched for age (48 
 

 
 3 years) and weight (86 
 

 
 6 kg)
served as controls. The data for the control subjects were taken
from a previous publication (17). ApoA-I kinetic data for hyper-
lipidemic patients at baseline were compared with data from a
group of healthy controls (age 25 
 

 
 0.4 years, mean body weight
73 
 

 
 2 kg). Plasma lipids and lipoproteins were analyzed accord-
ing to standard procedures (18). None of the study participants
had diabetes mellitus, cholestasis, nephrotic syndrome, pancre-
atitis, primary hypothyroidism, renal or hepatic dysfunction, or
chronic alcoholism. One patient (patient 7) suffering from pan-
hypopituitarism was on stable replacement doses of levothyrox-
ine, cortisol, recombinant human growth hormone, and testos-
terone throughout the study. Immunosuppressive agents, imidazole
antimycotics, macrolide antibiotics, 
 

 
 blocking agents, diuretics,
and isotretinoin were not allowed during the study period, nor
were lipid-lowering agents other than the study medication.
 
Study design
 
The study used an open, randomized, crossover design that
consisted of two treatment periods of 8 weeks each. After discon-
tinuing all preexisting lipid-lowering drugs, patients entered a 6
week run-in period and underwent the baseline apoB turnover
study during the last 2 weeks of this period. Thereafter, they were
randomized to receive either atorvastatin (80 mg/d) or micro-
nized fenofibrate (200 mg/d) for 8 weeks together with their
evening meal. After a washout period of 4 weeks, patients were
switched to the other study drug. ApoB turnover studies were
performed during the last 2 weeks of both treatment phases.
All patients received dietary counseling by a dietitian immedi-
ately after inclusion into the study protocol and two times there-
after, once during each treatment period. They were asked to fol-
low an isoenergetic diet containing 50% to 55% carbohydrates,
 
15% to 20% proteins, and 30% fats, with less than 300 mg of cho-
lesterol and less than 10% of total energy as saturated fatty acids.
Alcohol consumption of one drink or less per day was allowed,
and patients were asked to refrain from vigorous physical exer-
cise during the study period. Compliance with the dietary regi-
men was assessed by detailed food protocols of 3 days, including
1 weekend day, during each study period.
 
Study medication
 
The Clinical Pharmaceutical Operations Department of
Warner Lambert provided 40 mg atorvastatin tablets. Micronized
fenofibrate capsules (200 mg) were purchased from Fournier
Pharmaceutical Company (Schwarz Pharma AG, Switzerland).
Patients were instructed to take two atorvastatin 40 mg tablets or
one micronized fenofibrate 200 mg capsule together with their
evening meal during the treatment periods. Compliance with
the study medication was assessed by pill counting. The lipid-low-
ering drugs were well tolerated in all but one patient, who devel-
oped a macular rash during fenofibrate therapy and therefore
discontinued the drug.
 
Turnover protocol
 
The detailed procedures for conducting the turnover study
have been reported previously (19). In brief, subjects fasted for
11 h overnight before starting the study at 7 AM in a metabolic
ward. After insertion of intravenous lines for tracer administra-
tion and sample collection, controls received either an intrave-
nous bolus injection of d
 
3
 
-leucine (6.0 mg/kg body weight) or a
primed constant infusion (0.6 mg/kg, followed by 0.6 mg/kg per h
for 10 h). Patients received a modified primed constant infusion
(1.2 mg/kg, followed by 1.2 mg/kg per h for 5 h), which allowed
for a better definition of VLDL
 
1
 
 tracer enrichment. The total
dosage of tracer was nearly identical in all studies, and the three
dosage schemes had been compared in previous studies, includ-
ing the use of dual tracer applications (19, 20). In the first 10 h
period, patients and controls continued to fast but were allowed
noncaloric drinks and remained ambulatory in the metabolic
ward. At 6 PM, all study participants were allowed to leave the
hospital. Blood samples were collected in EDTA-containing tubes
before administration of tracer and thereafter at 0.16, 0.33, 0.5,
0.75, 1, 2, 4, 6, 8, 10, 12, 15, and 24 h in controls and at 0.25, 0.5,
1, 2, 3, 4, 5, 5.33, 5.66, 6, 7, 10, and 24 h in patients. The additional
samples taken in patients at 5, 5.33, and 5.66 h were necessary be-
cause of the rapid decline of plasma d
 
3
 
-leucine concentrations af-
ter stopping the tracer infusion. Further fasting samples were ob-
tained at approximately 8 AM daily for the next 10–14 days.
 
Lipoprotein isolation and preparation of apoB
 
The preparation of VLDL subfractions VLDL
 
1
 
 [Svedberg flo-
tation unit (S
 
f
 
) 60–400] and VLDL
 
2
 
 (S
 
f
 
 20–60), intermediate
density lipoprotein (IDL; S
 
f
 
 12–20), LDL (S
 
f
 
 0–12), LDL
 
1
 
 (S
 
f
 
6–12), and LDL
 
2
 
 (S
 
f
 
 0–6) has been described previously and is
based on the procedure of Lindgren, Jensen, and Hatch (19,
21). Briefly, 2 ml of plasma was adjusted to a density (
 
d
 
) of 1.118
g/ml by the addition of 0.03410 g of solid NaCl and layered over
a 0.5 ml cushion of 
 
d
 
 
 

 
 1.182 g/ml NaBr solution in a Beckman
SW 40 rotor tube. A discontinuous six-step salt gradient was con-
structed above this, and VLDL
 
1
 
, VLDL
 
2
 
, and IDL were harvested
as described (19). Finally, LDL
 
1
 
 and LDL
 
2
 
 were isolated after fur-
ther centrifugation at 36,000 rpm for 5 h, 6 min and at 32,000
rpm for 12 h, 9 min, respectively. Total LDL was reconstituted by
mixing equal volumes of LDL
 
1
 
 and LDL
 
2
 
. From the infranatant,
the HDL fraction was prepared after adjusting density to 1.21 g/ml
by centrifugation at 40,000 rpm for 16 h in a Beckman 50.4 Ti
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rotor. From each apoB-containing lipoprotein fraction, apoB was
precipitated by the addition of an equal volume of isopropanol
at room temperature (22). The pellet was delipidated with etha-
nol-ether (3:1) and dried with ether until apoB remained as a
fine white protein pellet. HDL apoA-I was prepared by SDS-
PAGE using an apoA-I standard, and apoA-I-containing bands
were cut from the gel.
 
Preparation and analysis of leucine in apoB, apoA-I, 
and plasma
 
ApoB and apoA-I were hydrolyzed in glass tubes (Schott,
Mainz, Germany) in the presence of 0.5–1.0 ml of 6 N HCl at
110
 

 
C for 20–24 h. The amino acid hydrolysate was concentrated
in a vacuum concentrator centrifuge (Univapo 150 H; Uniequip,
Martinsried/Munich, Germany) and aliquoted into microvials
(Chromacol, Herts, UK). After complete removal of HCl, samples
were ready for derivatization and mass spectrometric analysis.
Proteins were precipitated from 1 ml of plasma by adding 1 ml
of TCA (10%), and amino acids were prepared from the super-
natant by cation-exchange chromatography using 2 ml columns
filled with Dowex AG-50W-X8 resin (H
 

 
-form, 50–100 mesh; Bio-
Rad, Richmond, CA). The amino acids that bound to the resin
were desorbed by 4 M NH
 
4
 
OH, which was subsequently removed
by evaporation in a vacuum pump (Univapo 150 H), transferred
into microvials, and dried again for derivatization.
The method used for the analysis of d
 
3
 
-leucine enrichment in
protein hydrolysates and plasma amino acids is presented in de-
tail elsewhere (19). Ion mass fragments at 
 
m/z
 
 277, 276, and 274
were monitored by selective ion recording. The 
 
m/z
 
 277:276 ratio
showed a linear relationship with isotopic enrichment over the
range 0.0–10.0% atom percent excess. The ratio of 
 
m/z
 
 277:276
was multiplied by an average value for the constant ratio of 
 
m/z
 
276:274 (determined repeatedly throughout the analytical run, it
shows no change over the range 0.0–10% atom percent excess),
and the resulting 
 
m/z
 
 277:274 values were used to calculate spe-
cific isotopic enrichments and tracer-tracee ratios (19).
 
Measurement of apoB and apoA-I masses in 
lipoprotein fractions
 
The apoB content of VLDL
 
1
 
, VLDL
 
2
 
, IDL, and LDL was deter-
mined as the difference between total and isopropanol-soluble
protein measured by the procedure of Lowry et al. (23). Because
more than 90% of plasma apoA-I is associated with HDL, the
plasma apoA-I concentration was considered to equal the HDL
apoA-I concentration. From apoB and apoA-I concentrations (in
milligrams per milliliter of plasma) and an estimate of the
plasma volume (4% of the body weight), apoB and apoA-I
plasma pools were determined for the lipoprotein fractions of in-
terest. The leucine content of the apoB and apoA-I pools was
then calculated assuming leucine contents of 12.12% and
15.68%, respectively.
 
Kinetic analyses and multicompartmental modeling
 
The change in tracer-tracee ratios with time in plasma and in
apoB in the four apoB-containing lipoprotein fractions, together
with the measured apoB pool size for VLDL
 
1
 
, VLDL
 
2
 
, IDL, and
LDL, was used as the data set for the derivation of apoB kinetic
parameters. 
 
Figure 1A
 
 shows the multicompartmental model of
apoB metabolism, which was constructed using the SAAM II
modeling program (SAAM Institute, Seattle, WA), the develop-
ment of which has been described (19). Briefly, its basic features
include a four-compartment representation of free leucine kinet-
ics (compartments 1–4), a sequence of lipoprotein compart-
ments accounting for the stepwise delipidation of VLDL
 
1
 
through VLDL
 
2
 
 and IDL to LDL (compartments 6, 7, 9, 10, 12,
and 14), plus the three remnant compartments 8, 11, and 13 for
VLDL
 
1
 
, VLDL
 
2
 
, and IDL particles that are removed directly from
plasma. Free leucine and the apoB-containing compartments 6,
9, 12, and 14 in the VLDL
 
1
 
, VLDL
 
2
 
, IDL, and LDL density range
are linked via delay compartment 5, which is set at 0.5 h, the time
required for apoB biosynthesis. Compartment 15 allows for some
intravascular/extravascular exchange of LDL, which is not ob-
served for less-dense lipoproteins. Typical examples of the time
courses of leucine tracer-tracee ratios measured in the four
apoB-containing lipoproteins VLDL
 
1
 
, VLDL
 
2
 
, IDL, and LDL at
baseline and during therapy with each of the study drugs are
shown in 
 
Fig. 2A
 
. Similarly, apoA-I kinetic data were derived
from changes in the tracer-tracee ratios in HDL apoA-I over time
and in the apoA-I pool size in this lipoprotein fraction. Figure 2B
shows a typical example of the time course of the leucine tracer-
tracee ratio in HDL-associated apoA-I. The model to describe
HDL apoA-I metabolism is shown in Fig. 1B and has been pub-
lished previously (24). As for the apoB model, compartments
1–4 describe plasma leucine metabolism. An intrahepatic delay
compartment accounts for hepatic synthesis and the secretion of
apoA-I and is connected to a single intravascular compartment
(compartment 6), from which apoA-I is cleared. The exchange
of apoA-I with an extracellular pool is accounted for by the addi-
tion of compartment 7 to the model.
 
Ethical considerations
 
All subjects participating in this study gave written informed
consent. The study was approved by the Ethics Committee of
Basel University Hospital.
 
Statistical analyses
 
All statistical analyses were performed using Statistica 6 soft-
ware (StatSoft, Inc., Tulsa, OK). Values are given as means 
 

 
SEM. Plasma lipids and lipoproteins during different treatments
were analyzed using Student’s 
 
t
 
-test. The effects of treatments on
lipoprotein kinetics data were assessed using the Wilcoxon test.
Pearson correlation coefficients were used to express the relation
between kinetic variables. Comparisons between patients at base-
line and controls were performed using the Kruskal-Wallis test.
 
RESULTS
 
Lipids and apoB and apoA-I kinetic data of patients and 
controls at baseline
Table 1
 
 demonstrates that both plasma total cholesterol
and triglycerides were increased markedly in patients
(7.23 
 

 
 1.39 and 8.84 
 

 
 7.38 mmol/l, respectively). Whereas
the increase in total cholesterol was secondary to the in-
creased VLDL cholesterol levels in most patients, some pre-
sented also with increased LDL cholesterol. Compared with
patients, age- and sex-matched controls showed signifi-
cantly lower plasma triglyceride concentrations and VLDL
cholesterol levels. Total and LDL cholesterol levels, how-
ever, did not differ significantly. HDL cholesterol levels
were decreased compared with those of both age- and sex-
matched and nonmatched normolipidemic controls.
 
Table 2
 
 demonstrates that in patients, there was a 2-fold
increase in apoB secretion into the VLDL
 
1
 
 density range
compared with controls. This was associated with de-
creased rates of transfer of VLDL
 
1
 
 to VLDL
 
2
 
 and a dimin-
ished fractional catabolic rate (FCR) of VLDL
 
1
 
. A sig-
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nificant negative correlation between VLDL
 
1
 
 apoB
concentrations and VLDL
 
1
 
 apoB transfer rates was ob-
served at baseline (
 
r
 
 
 

 
 
 
	
 
0.72, 
 
P
 
 
 

 
 0.04). Although the
conversion rate of VLDL
 
1
 
 to VLDL
 
2
 
 was delayed in pa-
tients, the marked increase in the VLDL
 
1
 
 apoB pool re-
sulted in an increase in the absolute amount of apoB
transferred from the VLDL
 
1
 
 to the VLDL
 
2
 
 compartment.
The consecutive increase in VLDL2 apoB pool size in pa-
tients was further enhanced by a lower rate of apoB trans-
fer from VLDL2 to IDL, which was only in part compen-
sated for by the enhanced direct catabolism of VLDL2.
Direct production of VLDL2 apoB was not different be-
tween the groups. Despite a slight but statistically signifi-
cant increase in IDL apoB production from VLDL2 in pa-
tients, the IDL apoB pool size was similar in patients and
controls (Tables 3, 4; Fig. 3) Finally, LDL apoB kinetic pa-
rameters did not differ significantly, although there was a
trend toward higher LDL apoB FCR in patients (Table 5,
Fig. 3). Furthermore, both LDL cholesterol and LDL apoB
concentrations were inversely correlated with the rate of
LDL catabolism in our patients at baseline (r  	0.85, P 
0.002 and r  	0.89, P  0.006, respectively). The lipid
composition of VLDL1 and VLDL2 particles in patients
and controls was comparable (data not shown). Thus, the
observed differences in triglyceride and VLDL cholesterol
concentrations in our patients were accounted for by he-
patic oversecretion, impaired direct catabolism, and de-
layed delipidation of normally composed VLDL1. This led
to an increase in the number of VLDL2 particles, which were
also metabolized more slowly, further contributing to the
observed hypertriglyceridemia and hypercholesterolemia.
The decrease in plasma HDL cholesterol concentra-
tions was in part accounted for by compositional changes
of HDL particles, which were triglyceride enriched (9.6 
1.2 vs. 3.5  0.4%; P  0.001) and cholesterol depleted
(11.6  0.6 vs. 17.6  0.6%; P  0.001) compared with the
group of non age- and sex-matched controls. The lower
apoA-I plasma concentrations in hypertriglyceridemic
subjects (1.13  0.07 vs. 1.33  0.10; P  0.046) were asso-
ciated with a trend toward an increase in apoA-I catabo-
lism [0.21  0.02 vs. 0.28  0.02; P  0.093 (Table 6)].
Effects of atorvastatin and fenofibrate on plasma lipids, 
apolipoproteins, and apoB and apoA-I kinetics
Therapy with atorvastatin (80 mg/d) decreased total,
VLDL, and LDL cholesterol by 39%, 52%, and 40%, re-
Fig. 1. A: Multicompartmental model of apolipoprotein
B (apoB) metabolism. Because plasma-free tracer kinetics
are fully accounted for, both bolus and primed constant
infusion data could be analyzed using the same model.
Plasma leucine is represented by a compartment (com-
partment 1) that received the tracer and distributed it to
body protein pools (compartments 3 and 4) and an intra-
cellular compartment (compartment 2) that was the pre-
cursor to apoB synthesis. Compartment 5 represents an in-
trahepatic pool accounting for the delay (0.5 h) associated
with the synthesis of apoB, lipoprotein assembly, and se-
cretion. Compartments 6–9, 12, and 14 form a delipida-
tion chain, and tracer appeared throughout this chain,
i.e., in VLDL1 (compartment 6), VLDL2 (compartment 9),
intermediate density lipoprotein (IDL; compartment 12),
and LDL (compartment 14). Compartments 8, 11, and 13
represent lipoprotein remnants that are directly removed
from the circulation. Compartment 15 accounts for an ex-
travascular exchange of LDL, which does not occur for the
other apoB-containing lipoproteins. A detailed descrip-
tion of the model is given in ref. (19). B: Multicompart-
mental model of apolipoprotein A-I (apoA-I) metabolism.
Plasma leucine is represented by a compartment (com-
partment 1) that received the tracer and distributed it to
body protein pools (compartments 3 and 4) and an intra-
cellular pool (compartment 2). Compartment 5 repre-
sents an intrahepatic pool accounting for the delay (0.15 h)
associated with the synthesis of apoA-I, lipoprotein assem-
bly, and secretion. All tracer input into HDL apoA-I occurs
in a single compartment (compartment 6) from which
apoA-I is cleared. Compartment 7 accounts for an ex-
travascular HDL pool.  by guest, on Novem
ber 21, 2017
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spectively (P  0.02). Fasting triglycerides decreased by
57%, and a statistically significant 18% increase in HDL
cholesterol was observed (P  0.02). Whereas plasma tri-
glycerides and VLDL cholesterol were decreased equally
during fenofibrate therapy (	57% and 	54%; P  0.02),
the decrease of plasma total cholesterol was significantly
less-pronounced compared with that during atorvastatin
therapy (	17%; P  0.03 and 0.02 vs. baseline and atorva-
statin, respectively). With fenofibrate therapy, LDL choles-
terol and apoB plasma concentrations remained un-
changed. Furthermore, the increase in the ratio of LDL1
to LDL2 during fenofibrate therapy indicated a shift of
LDL particle size toward larger, buoyant LDLs.
ApoB kinetic data revealed a marked decrease in VLDL1
apoB pool size during treatment with atorvastatin (	62%;
P  0.012), attributable to an increased fractional transfer
rate of VLDL1 apoB to VLDL2 (140%; P  0.012). Fur-
thermore, direct hepatic VLDL1 apoB production de-
Fig. 2. Tracer-tracee ratios recorded after a primed constant infusion of deuterated leucine as a metabolic tracer. ApoB from VLDL1,
VLDL2, IDL, and LDL (A) and apoA-I from HDL (B) at baseline and during atorvastatin and fenofibrate treatment are shown from patient 7.
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creased in six of eight patients. Remarkably, the patients
showing no decrease of VLDL1 production when treated
with atorvastatin (patients 5 and 8) had the lowest VLDL1
production rates at baseline and experienced a pronounced
increase in VLDL1 direct catabolism (Table 2, Fig. 3).
Because direct hepatic VLDL2 production and input of
apoB from VLDL1 did not change, the lower VLDL2 apoB
pool in atorvastatin-treated subjects (	43%; P  0.012)
was attributable to enhanced direct removal of VLDL2
particles from the circulation (67%; P  0.035). IDL
and LDL apoB pools were reduced by atorvastatin therapy
(	48% and 	33%, respectively; P  0.012). Direct he-
patic production rates of these lipoproteins were not al-
tered, but there was a trend toward a faster elimination of
IDL particles. The reduction of LDL apoB pool size with
atorvastatin therapy resulted from both decreased LDL apoB
production and increased LDL catabolism. LDL produc-
tion, defined as the sum of direct secretion and input
from IDL, was reduced significantly (	24%; P  0.05),
whereas LDL FCR was increased in seven of eight patients.
The striking effect of fenofibrate on VLDL1 apoB pool
size resulted from both enhanced direct catabolism
(239%; P  0.043) and increased fractional transfer to
VLDL2 (147%; P  0.018). Hepatic VLDL1 apoB secre-
tion was not significantly affected. Additionally, a marked
acceleration of the delipidation of VLDL2 was observed
TABLE 1. Lipid and lipoprotein values in controls and in patients at baseline and during atorvastatin 
and fenofibrate therapy
Subjects Cholesterol Triglycerides
VLDL 
Cholesterol
LDL 
Cholesterol
HDL 
Cholesterol apoB apoA-I LDL1/LDL2
mmol/l g/l
Controls
C1 5.64 1.16 0.49 3.67 1.50
C2 5.53 0.76 0.34 3.98 1.19
C3 6.34 1.39 0.57 4.50 1.29
C4 6.93 1.60 0.75 5.30 0.93
C5 6.26 1.94 0.80 4.16 1.32
C6 6.93 1.55 0.85 4.99 1.09
C7 6.21 2.10 1.24 4.09 0.85
C8 6.23 2.39 0.96 3.54 0.96
Mean 6.26 1.61 0.75 4.28 1.14
SEM 0.18 0.19 0.10 0.22 0.08
Patients
Baseline
P1 9.90 26.13 7.03 2.38 0.49 1.11 0.87 0.84
P2 7.16 11.36 2.87 3.41 0.88 1.44 1.22 0.40
P3 6.47 7.51 3.34 2.38 0.78 1.25 1.04 0.76
P4 6.21 7.11 2.59 2.87 0.70 1.22 0.99 0.36
P5 6.26 5.37 2.64 2.72 0.88 1.05 1.39 0.37
P6 6.98 4.98 2.09 4.06 0.83 1.47 1.17 1.06
P7 8.79 4.56 2.12 5.92 0.67 1.95 1.03 0.45
P8 6.10 3.74 1.66 3.62 0.83 1.40 0.97 0.63
Mean 7.23 8.84a 3.04b 3.42 0.76b 1.36 1.09 0.61
SEM 0.49 2.61 0.60 0.42 0.05 0.10 0.06 0.09
Atorvastatin
P1 3.90 4.65 2.15 1.19 0.57 0.80 0.87 0.69
P2 5.07 3.32 1.40 2.56 1.11 1.05 1.26 0.73
P3 3.78 3.94 1.47 1.29 1.03 0.74 1.21 0.32
P4 3.85 3.33 1.45 1.73 0.70 0.88 0.94 0.30
P5 3.90 2.61 1.16 1.66 1.11 0.73 1.43 0.52
P6 4.47 3.00 1.34 2.17 0.96 0.91 1.22 0.51
P7 4.73 2.51 1.14 2.79 0.80 1.10 1.04 0.70
P8 4.50 1.40 0.65 2.95 0.91 1.08 1.03 0.55
Mean 4.28c,d 3.09e 1.34c 2.04c,d 0.90c 0.91c,d 1.13 0.54d
SEM 0.17 0.35 0.15 0.24 0.07 0.05 0.07 0.06
Fenofibrate
P1 5.66 6.88 2.66 2.40 0.59 1.12 1.03 1.90
P2 6.65 3.59 1.32 4.32 1.03 1.50 1.30 0.78
P3 5.20 2.34 1.06 3.18 0.96 1.21 1.11 1.19
P5 5.07 2.13 0.93 2.87 1.27 1.00 1.57 1.50
P6 5.53 2.53 1.03 3.41 1.09 1.18 1.35 1.97
P7 7.03 2.17 0.91 5.33 0.80 1.65 1.02 1.19
P8 6.44 2.71 1.29 4.42 0.83 1.53 1.04 0.86
Mean 5.94e 3.19e 1.32c 3.71 0.94c 1.31 1.20c 1.34c
SEM 0.29 0.64 0.23 0.39 0.08 0.09 0.08 0.18
apoB, apolipoprotein B; apoA-I, apolipoprotein A-I; C1–C8, controls 1–8; P1–P8, patients 1–8.
a P  0.05 versus controls.
b P  0.01 versus controls.
c P  0.01 versus baseline.
d P  0.01 versus fenofibrate.
e P  0.05 versus baseline.
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(79%; P  0.018), whereas no consistent effect on the di-
rect catabolism of VLDL2 could be demonstrated. The in-
crease in fractional catabolism of IDL (168%; P  0.028)
during fenofibrate therapy prevented an increase in IDL
apoB pool size secondary to enhanced transfer from
VLDL2 to IDL. In contrast to the effects of fenofibrate on
IDL precursors in the delipidation chain, the transforma-
tion of IDL to LDL was not stimulated. LDL apoB catabo-
lism was decreased in all but one patient during fenofibrate
treatment, leading to a statistically significant decrease
(	17%; P  0.018). ApoB pool size was significantly lower
after therapy with atorvastatin compared with fenofibrate.
Although atorvastatin and fenofibrate increased HDL
cholesterol levels to a similar degree (18% and 22%; P 
0.017 and 0.027, respectively), apoA-I plasma concentrations
were only increased by fenofibrate. In accordance with this
finding, no effects of atorvastatin on apoA-I kinetic parame-
ters were found, whereas fenofibrate therapy increased both
apoA-I production and, to a lesser extent, apoA-I catabolism
(37% and 21%, respectively; P  0.05). Both atorvastatin
and fenofibrate similarly reduced the triglyceride content of
HDL particles (	34% and 	38%, respectively; P  0.05).
DISCUSSION
The present study provides a new additional explana-
tion for the distinct triglyceride-lowering effect of the
TABLE 2.  VLDL1 apoB kinetics in controls and in patients at 
baseline and during atorvastatin and fenofibrate therapy
Subjects Production Pool Transfer FCR
mg/kg/day mg pools/day
Controls
C1 12.05 59 9.90 7.20
C2 7.37 27 10.40d 9.80
C3 26.59 123 5.70 11.10
C4 12.10 127 5.90 4.00
C5 11.47 136 3.20 1.70
C6 6.67 78 7.60 0.10
C7 13.95 150 4.00 6.30
C8 15.47 193 3.90 3.20
Mean 13.21 112 6.33 5.43
SEM 2.18 19 0.97 1.37
Patients
Baseline
P1 22.11 1,515 0.49 0.72
P2 47.72 1,023 1.27 2.69
P3 29.13 1,102 1.49 1.13
P4 26.36 847 1.98 1.35
P5 14.66 610 1.04 0.68
P6 29.06 673 2.49 1.48
P7 20.10 453 1.27 2.02
P8 19.56 430 2.48 1.03
Mean 26.09a 832a 1.56a 1.39a
SEM 3.56 131 0.25 0.24
Atorvastatin
P1 15.11 479 2.40 0.22
P2 17.78 355 1.82 2.43
P3 9.90 341 2.83 0.05
P4 17.12 425 2.25 2.06
P5 25.13 310 2.37 3.46
P6 20.37 296 6.15 0.18
P7 15.59 190 4.21 1.87
P8 22.80 160 7.97 3.00
Mean 17.98 320b 3.75b 1.66c
SEM 1.69 38 0.78 0.48
Fenofibrate
P1 29.77 614 2.56 1.46
P2 43.40 371 3.49 6.44
P3 20.04 190 3.11 7.34
P5 28.40 149 4.67 9.10
P6 17.75 215 4.09 3.52
P7 21.89 198 3.24 4.93
P8 16.05 207 5.83 0.15
Mean 25.33 278d 3.86d 4.71d
SEM 3.58 62 0.42 1.22
FCR, fractional catabolic rate.
a P  0.01 versus controls.
b P  0.01 versus baseline.
c P  0.05 versus fenofibrate (Wilcoxon test).
d P  0.05 versus baseline.
TABLE 3.  VLDL2 apoB kinetics in controls and in patients at 
baseline and during atorvastatin and fenofibrate therapy
Subjects Production Flux Pool Transfer FCR
mg/kg/day mg pools/day
Controls
C1 3.37 6.98 114 7.30 0.20
C2 3.61 3.79 96 4.20 0.50
C3 4.67 9.01 182 5.00 0.80
C4 2.21 7.22 236 2.20 0.10
C5 1.55 7.50 156 3.20 0.20
C6 6.20 6.56 267 1.80 0.00
C7 4.17 5.47 462 2.20 0.00
C8 3.98 8.46 321 3.00 0.40
Mean 3.72 6.87 229 3.61 0.28
SEM 0.51 0.59 43 0.65 0.10
Patients
Baseline
P1 12.24 9.02 1,656a 0.38 0.69
P2 6.29 15.31 487 1.39 2.38
P3 2.14 16.57 513 2.05 1.56
P4 4.48 15.70 654 1.97 1.34
P5 2.96 8.86 365 2.30 0.03
P6 1.99 18.25 438 2.67 1.58
P7 5.13 7.76 500 1.91 0.00
P8 4.17 13.84 447 2.20 0.91
Mean 4.93 13.16a 633a 1.86b 1.06b
SEM 1.17 1.43 149 0.25 0.29
Atorvastatin
P1 5.28 13.84 528 1.56 1.44
P2 9.47 7.62 354 1.69 2.41
P3 3.44 9.74 512 1.23 1.32
P4 10.20 8.94 517 1.96 2.00
P5 2.42 10.21 189 1.95 2.86
P6 3.42 19.79 281 5.79 1.81
P7 0.28 10.80 318 2.23 0.35
P8 0.46 16.57 181 5.26 1.98
Mean 4.37 12.19 360c 2.71 1.77d,e
SEM 1.33 1.48 51 0.63 0.27
Fenofibrate
P1 3.81 18.95 760 1.58 0.90
P2 2.78 15.27 349 4.32 0.08
P3 2.72 5.97 273 2.97 0.18
P5 0.00 9.64 148 3.50 1.20
P6 4.73 9.54 281 3.69 0.98
P7 4.62 8.69 208 3.73 1.00
P8 2.35 15.65 388 2.73 0.84
Mean 3.00 11.96 344d 3.22d 0.74
SEM 0.61 1.77 76 0.34 0.16
a P  0.01 versus controls.
b P  0.05 versus controls (Kruskal-Wallis test).
c P  0.01 versus baseline.
d P  0.05 versus baseline.
e P  0.05 versus fenofibrate (Wilcoxon test).
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HMG-CoA reductase inhibitor atorvastatin in subjects
with mixed hyperlipidemia and contrasts its actions with
those obtained during administration of fenofibrate, a fi-
brate derivative and PPAR agonist.
The marked increase of triglyceride plasma concentra-
tions in patients compared with controls was secondary to
an increase in the number of circulating lipoprotein parti-
cles in the VLDL1 and VLDL2 density range, because the
lipid composition of these lipoproteins remained un-
changed. A marked increase in the hepatic production of
VLDL1, a pronounced delay in the delipidation of VLDL1
to VLDL2 and VLDL2 to IDL, and a decrease in the direct
catabolism of VLDL1 accounted for the changes of plasma
lipoprotein concentrations observed. These findings in
the basal state are in agreement with the results of several
other apoB kinetic studies in patients with mixed hyper-
lipidemia showing both increased production of composi-
tionally unaltered VLDL and delayed removal (25–28).
The increased LDL cholesterol levels in some subjects
were accounted for by lower LDL catabolic rates.
The decrease of HDL cholesterol and apoA-I concen-
trations in our hypertriglyceridemic subjects agrees with
previously reported data (29). These changes were associ-
ated with an increase in HDL triglyceride content and ac-
celerated apoA-I catabolism. In the presence of excess cir-
culating triglyceride-rich lipoproteins, cholesterol ester
transfer protein (CETP) mediates the reciprocal transfer
of triglycerides from triglyceride-rich lipoproteins to HDL
in exchange for cholesterol esters, thereby generating tri-
glyceride-enriched HDL. Triglyceride-rich HDLs, how-
ever, are more suscpetible to lipolytic modification by he-
patic lipase, resulting in the formation of small, dense
HDL particles, which are then more easily catabolized.
This mechanism provides an explanation for the findings
of our study (30, 31). Statins have consistently been shown
to decrease plasma LDL cholesterol in response to an in-
crease in hepatic LDL receptor expression and hence in-
creased catabolism of apoB-containing lipoproteins (10).
The increased catabolism of VLDL2, IDL, and LDL apoB
in most of our patients during atorvastatin treatment and
the results of other recent apoB kinetic studies in subjects
with mixed hyperlipidemia support this mechanism (32–
Fig. 3. Turnover of apoB in controls and patients at baseline and
after 8 weeks of therapy with atorvastatin and fenofibrate. Mean
apoB pool sizes (milligrams) in each lipoprotein fraction are shown
in circles. Direct hepatic production and flux rates are given in mil-
ligrams per kilogram of body weight per day (open arrows). Frac-
tional transfer rates and fractional rates of direct catabolism (pools
per day, closed arrows) are shown in italic.
TABLE 4.  Intermediate density lipoprotein apoB kinetics in 
controls and in patients at baseline and during atorvastatin 
and fenofibrate therapy
Subjects Production Flux Pool Transfer FCR
mg/kg/day mg pools/day
Controls
C1 1.57 10.08 433 1.69 0.55
C2 2.87 5.61 321 1.92 0.32
C3 1.86 11.65 488 1.85 0.31
C4 0.82 4.93 498 1.20 0.89
C5 0.24 8.66 370 1.14 0.25
C6 0.01 5.19 527 0.89 1.29
C7 3.87 9.20 663 2.19 0.07
C8 2.99 10.89 505 1.60 0.85
Mean 1.78 8.28 476 1.56 0.57
SEM 0.49 0.95 37 0.16 0.15
Patients
Baseline
P1 3.14 7.53 1,077 0.44 0.38
P2 3.87 7.96 330 3.05 0.00
P3 1.18 10.64 384 2.69 0.35
P4 0.27 12.02 502 1.71 0.91
P5 1.24 11.69 291 2.97 0.23
P6 0.46 12.71 782 1.55 0.00
P7 0.28 12.89 572 0.83 0.89
P8 0.59 12.75 438 1.60 0.75
Mean 1.38 11.02a 547 1.86 0.44
SEM 0.49 0.76 94 0.34 0.13
Atorvastatin
P1 1.78 9.94 280 1.13 2.34
P2 5.24 7.07 306 2.83 0.59
P3 2.53 6.36 204 2.54 1.77
P4 0.28 9.48 283 3.28 0.40
P5 1.68 5.13 167 2.88 0.06
P6 1.45 17.68 431 1.36 2.72
P7 1.26 9.58 285 1.78 1.03
P8 1.01 12.37 317 2.72 0.53
Mean 1.90 9.70 284b,c 2.32 1.18
SEM 0.53 1.40 28 0.28 0.35
Fenofibrate
P1 0.84 14.49 634 1.00 1.00
P2 6.53 17.73 351 3.00 2.88
P3 1.92 8.20 366 1.93 0.81
P5 2.74 7.19 247 2.20 0.69
P6 1.32 11.27 462 1.60 0.99
P7 1.62 10.48 435 1.34 0.72
P8 3.32 13.77 548 1.22 1.18
Mean 2.61 11.88 435 1.76 1.18d
SEM 0.73 1.40 49 0.26 0.29
a P  0.05 versus controls (Kruskal-Wallis test).
b P  0.01 versus baseline.
c P  0.05 versus fenofibrate (Wilcoxon test).
d P  0.05 versus baseline.
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37). In accordance, the decrease in LDL apoB synthesis
found by us and other investigators is likely to result from
the enhanced removal of LDL precursors via the LDL re-
ceptor pathway (38–40). Interestingly, the extent of the
atorvastatin-associated increase in LDL apoB catabolism
in our study was clearly correlated with the LDL apoB con-
centration and the LDL apoB turnover rate at baseline
(Fig. 4). Thus, subjects with the highest LDL apoB con-
centrations and the lowest catabolic rates experienced the
most pronounced increase in LDL apoB catabolism dur-
ing atorvastatin treatment. This suggests that the extent of
increase in LDL catabolism secondary to statins is depen-
dent on the baseline metabolic state and offers an expla-
nation for the previous observation of a correlation be-
tween baseline LDL cholesterol concentrations and the
extent of their decrease during simvastatin therapy (41).
However, two additional mechanisms contributed to the
lipid-lowering mechanism of atorvastatin in our study.
First, atorvastatin-treated subjects demonstrated a 2.4-fold
increase in the delipidation of VLDL1 to VLDL2. This
finding is in agreement with recently reported results
from other apoB kinetic studies (36, 37). Removal of tri-
glycerides from circulating triglyceride-rich lipoproteins is
mediated by lipoprotein lipase (LPL). The activity of this
enzyme is critically dependent on its cofactor apoC-II,
whereas apoC-III has been found to be inhibitory (42).
Simvastatin has recently been described to increase LPL
activity and mRNA in rat heart and adipose tissue, and this
was ascribed to a decrease of liver apolipoprotein C-III
(apoC-III) mRNA expression (43). In analogy, it can be
speculated that the triglyceride-lowering effect of atorva-
TABLE 5. LDL apoB kinetics in controls and in patients at baseline 
and during atorvastatin and fenofibrate therapy
Subjects Production Flux Pool FCR
mg/kg per day mg pools/day
Controls
C1 0.01 8.81 2,612 0.28
C2 4.97 8.20 2,219 0.44
C3 3.47 11.55 2,791 0.42
C4 0.02 5.77 3,407 0.18
C5 0.47 7.29 1,901 0.24
C6 0.92 5.21 3,003 0.18
C7 0.02 13.07 3,853 0.38
C8 0.01 9.06 2,892 0.28
Mean 1.24 8.62 2,835 0.30
SEM 0.68 0.95 220 0.04
Patients
Baseline
P1 0.51 5.73 919 0.56
P2 1.93 11.83 2,933 0.40
P3 0.69 10.46 2,439 0.45
P4 1.14 8.02 2,371 0.41
P5 1.37 11.99 1,776 0.54
P6 0.40 13.17 3,653 0.34
P7 1.87 6.38 3,334 0.18
P8 0.83 9.09 2,648 0.29
Mean 1.09 9.58 2,509 0.40
SEM 0.21 0.97 307 0.04
Atorvastatin
P1 0.00 3.82 644 0.49
P2 2.42 10.19 2,432 0.44
P3 0.34 5.24 1,062 0.52
P4 0.24 8.68 2,082 0.46
P5 1.40 6.67 1,001 0.58
P6 0.88 6.36 1,818 0.37
P7 0.00 6.88 2,001 0.25
P8 0.53 11.21 2,467 0.37
Mean 0.73 7.38 1,688a,b 0.44b
SEM 0.29 0.88 246 0.04
Fenofibrate
P1 0.00 7.65 1,317 0.48
P2 0.00 12.37 3,147 0.33
P3 4.27 7.14 3,028 0.37
P5 2.03 7.55 1,707 0.40
P6 1.47 8.04 2,979 0.29
P7 1.92 7.84 3,461 0.21
P8 1.72 8.68 3,209 0.25
Mean 1.63 8.47 2,693 0.33c
SEM 0.55 0.67 313 0.03
a P  0.01 versus baseline.
b P  0.05 versus fenofibrate (Wilcoxon test).
c P  0.05 versus baseline.
TABLE 6. HDL apoA-I kinetics in controls and in patients at baseline 
and during atorvastatin and fenofibrate therapy
Subjects Production Pool FCR
mg/kg/day mg pools/day
Controls
C1 16.2 3,763 0.30
C2 8.3 3,248 0.18
C3 7.1 3,093 0.17
C4 6.8 4,146 0.14
C5 6.3 2,602 0.15
C6 19.1 5,266 0.28
C7 14.0 4,016 0.26
C8 14.1 4,768 0.21
Mean 11.49 3,863 0.21
SEM 1.75 312 0.02
Patients
Baseline
P1 9.7 2,810 0.28
P2 11.6 4,009 0.24
P3 10.4 3,982 0.25
P4 15.0 4,181 0.38
P5 13.3 3,971 0.24
P6 10.4 4,176 0.22
P7 9.5 3,090 0.23
P8 14.3 3,074 0.37
Mean 11.78 3,662 0.28
SEM 0.76 200 0.02
Atorvastatin
P1 9.6 2,849 0.27
P2 19.3 4,233 0.38
P3 14.8 4,744 0.30
P4 10.3 4,026 0.27
P5 11.4 4,076 0.20
P6 11.6 4,552 0.23
P7 9.1 3,056 0.23
P8 8.4 3,173 0.20
Mean 11.81a 3,839 0.26
SEM 1.28 254 0.02
Fenofibrate
P1 16.0 3,384 0.38
P2 16.4 4,380 0.31
P3 20.7 4,256 0.47
P5 20.1 4,484 0.32
P6 14.5 4,956 0.26
P7 13.2 2,990 0.32
P8 12.3 3,018 0.31
Mean 16.17b 3,924 0.34b
SEM 1.22 296 0.03
a P  0.05 versus fenofibrate (Wilcoxon test).
b P  0.05 versus controls (Kruskal-Wallis test).
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statin in our patients was at least in part secondary to an
increase in LPL activity resulting from decreased apoC-III
levels. This may result from the activation of the nuclear
receptor PPAR, which has recently been implicated as a
mediator of statin effects on lipid metabolism (44). Sec-
ond, hepatic secretion of VLDL1 apoB, which accounted
for 78% of total apoB secretion in the basal state, de-
creased in six patients, a finding in agreement with some,
but not all, previous apoB kinetic studies of patients with
mixed hyperlipidemia (34, 36, 39, 40). As recently re-
viewed in detail, these discrepancies may be explained by
different underlying metabolic conditions in the subjects
enrolled in these studies (40). Hepatic apoB secretion has
been shown to be largely substrate-driven (45). The find-
ing of a decreased VLDL1 cholesterol ester content (3.9
vs. 6.6%; P  0.001; data not shown) supports the view
that a decrease of hepatocellular cholesterol levels sec-
ondary to statin treatment may limit the intracellular avail-
ability of cholesterol esters to form mature lipoproteins
and hence impair hepatic lipoprotein secretion (46).
Therefore, the profound triglyceride- and cholesterol-low-
ering effects of atorvastatin in mixed hyperlipidemia re-
sult from both the decreased production and accelerated
breakdown and removal of triglyceride-rich lipoproteins,
whereas maintaining a high rate of LDL catabolism pre-
vents an increase in LDL after enhanced delipidation of
its precursors. The absence of an effect of atorvastatin on
apoA-I kinetics agrees with findings from previous kinetic
studies of normolipidemic subjects and patients with the
metabolic syndrome (37, 47). Therefore, the beneficial ef-
fects of atorvastatin on HDL metabolism seem to be sec-
ondary to its effect on the metabolism of triglyceride-rich
lipoproteins and the resulting decrease of core lipid ex-
change between these lipoprotein fractions.
Therapy with fibrates such as fenofibrate has consis-
tently been shown to decrease plasma VLDL cholesterol
and triglyceride levels and to increase HDL cholesterol,
thereby favorably influencing the cardiovascular risk pro-
file. With regard to LDL cholesterol, both increased and
decreased plasma concentrations have been observed,
and the fibrate effect seemed to be largely dependent on
the pretreatment lipid phenotype (48). Fibrate effects on
lipid metabolism result from the activation of the nuclear
receptor PPAR, an important regulator of genes involved
in the oxidation of fatty acids, lipogenesis, intravascular
catabolism of triglyceride-rich lipoproteins, and reverse
cholesterol transport (16). Decreased hepatic triglyceride
production secondary to the decreased availability of fatty
acids and accelerated delipidation and removal of VLDL
attributable to enhanced LPL activity have been found to
be consistent effects of fibrates in vivo (49–51). Previous
kinetic studies in patients with endogenous hypertriglycer-
idemia or the metabolic syndrome using either bezafi-
brate or fenofibrate reported an increase of VLDL apoli-
poprotein catabolism but no change in VLDL apoB
production (37, 52).
The kinetic data obtained in this study demonstrate
that the triglyceride-lowering effect of fenofibrate results
from both enhanced direct removal and delipidation of
VLDL1. The VLDL1 transfer rate during fenofibrate ther-
apy was inversely correlated with the baseline status, indi-
cating that fenofibrate was most effective in patients with a
low VLDL1 turnover at baseline (Fig. 4). Furthermore,
VLDL2 particles were more rapidly converted to IDL and
then removed from the circulation. ApoB production in
the VLDL1 or VLDL2 density range was unaffected. Be-
cause the lipid composition of VLDL remained unaltered,
this suggests that fenofibrate did not interfere with the he-
patic secretion of triglyceride-rich lipoproteins in our pa-
tients. Whether the lack of a fenofibrate effect on hepatic
lipoprotein production is substance specific or a conse-
quence of the underlying metabolic defect in our patients
is unclear.
Regarding LDL metabolism, previous kinetic studies us-
ing radioisotopes clearly suggested that the effects of fi-
brates depend on the underlying lipid disorder. In sub-
jects with hypercholesterolemia, fenofibrate, bezafibrate,
and ciprofibrate decreased LDL cholesterol by enhancing
receptor-mediated clearance (53–55). In moderate to se-
vere hypertriglyceridemic subjects, however, LDL is rela-
tively triglyceride rich and its catabolic rate is often mark-
edly increased. Treatment with fenofibrate results in a
normalization of LDL composition, a decrease in the LDL
FCR, and thereby an increase of the LDL cholesterol
plasma level. Fenofibrate also induces a shift from small,
Fig. 4. The response of LDL apoB catabolism to atorvastatin was
most pronounced in patients with high LDL apoB concentrations
(A) and low LDL catabolic rates (B) at baseline. Patients with low
VLDL1 fractional transfer rates (FTR) at baseline showed the greatest
response to fenofibrate therapy (C). FCR, fractional catabolic rate.
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dense to larger, buoyant LDLs (56). These observations
were all confirmed in the present study.
Fenofibrate resulted in an increase of apoA-I catabolism
that was more than compensated for by a concomitant in-
crease in the rate of apoA-I production. As a net result,
apoA-I and thereby HDL turnover in plasma was in-
creased, which conceivably is beneficial with regard to the
role of HDL in reverse cholesterol transport. These find-
ings are in agreement with the results of some, but not all,
studies reporting apoA-I kinetic data in patients treated
with various fibrates (37, 52, 53, 57). Differences between
the underlying lipid disorders, the fibrate derivatives used,
and the study designs may explain these discrepancies. Di-
rect transcriptional effects of PPAR activation on the he-
patic apoA-I gene seem to account for the increased he-
patic apoA-I production observed (16). The increase in
apoA-I catabolism found in this and other studies may be
explained by the enhanced intravascular remodeling of
HDL2 to small, dense, more easily catabolized HDL3 sec-
ondary to the activation of hepatic lipase by fenofibrate
(58). In analogy to the findings obtained during atorvasta-
tin treatment, the marked reduction in the concentra-
tions of triglyceride-rich lipoproteins were associated with
a decrease in HDL triglyceride content and reciprocal
changes in HDL cholesterol levels.
In summary, the results of this study demonstrate that
in patients with moderate to severe mixed hyperlipidemia
attributable to both the overproduction and delayed re-
moval of VLDL, atorvastatin and fenofibrate are equally
effective at decreasing plasma triglycerides. Both drugs ac-
celerate the delipidation of VLDL1, presumably by in-
creasing LPL activity. Additionally, atorvastatin enhances
the removal of VLDL2 from plasma, and fenofibrate in-
creases the direct catabolism of VLDL1. Decreased apoB
and LDL cholesterol plasma concentrations with atorva-
statin therapy can be ascribed to increased rates of LDL
catabolism and the removal of LDL precursors from the
circulation, suggesting that statins may be particularly effi-
cacious in subjects with increased triglycerides and LDL
cholesterol levels. In contrast, fenofibrate did not de-
crease LDL cholesterol effectively, although it induced a
normalization of the LDL subfraction distribution. Whereas
atorvastatin only normalized HDL composition but left
apoA-I metabolism largely unaffected, fenofibrate increased
HDL cholesterol concentrations and plasma turnover by
increasing the rates of apoA-I production and catabo-
lism.
This study was supported by a grant from Warner Lambert
Parke Davis (Baar, Switzerland).
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